MedPath
FDA Approval

Eptifibatide

FDA-approved pharmaceutical product with comprehensive regulatory information, manufacturing details, and complete labeling documentation.

FDA Approval Summary

Effective Date
April 21, 2022
Labeling Type
HUMAN PRESCRIPTION DRUG LABEL
Eptifibatide(2 mg in 1 mL)

Manufacturing Establishments1

FDA-registered manufacturing facilities and establishments involved in the production, packaging, or distribution of this drug product.

Hainan Shuangcheng Pharmaceuticals Co., Ltd.

Hainan Shuangcheng Pharmaceuticals Co., Ltd.

421282282

Products2

Detailed information about drug products covered under this FDA approval, including NDC codes, dosage forms, ingredients, and administration routes.

Eptifibatide

Product Details

NDC Product Code
52958-402
Application Number
ANDA213081
Marketing Category
ANDA (C73584)
Route of Administration
INTRAVENOUS
Effective Date
April 21, 2022
Code: NA8320J834Class: ACTIBQuantity: 2 mg in 1 mL
Sodium HydroxideInactive
Code: 55X04QC32IClass: IACT
Citric Acid MonohydrateInactive
Code: 2968PHW8QPClass: IACTQuantity: 5.25 mg in 1 mL

Eptifibatide

Product Details

NDC Product Code
52958-040
Application Number
ANDA213081
Marketing Category
ANDA (C73584)
Route of Administration
INTRAVENOUS
Effective Date
April 21, 2022
Code: NA8320J834Class: ACTIBQuantity: 0.75 mg in 1 mL
Citric Acid MonohydrateInactive
Code: 2968PHW8QPClass: IACTQuantity: 5.25 mg in 1 mL
Sodium HydroxideInactive
Code: 55X04QC32IClass: IACT
© Copyright 2025. All Rights Reserved by MedPath